drugset
drugset / Trial / NCT07181135

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

NCT07181135 ↗

Phase 3 Enrolling by invitation 180 enrolled University Medical Center Groningen
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to demonstrate efficacy of finerenone when compared to placebo in reducing albuminuria in participants with chronic kidney disease (CKD) not using renin-angiotensin-system (RAS) inhibitors.

Timeline

Start
2026-03-13
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Finerenone Small molecule 10 mg Oral
Subject Finerenone Small molecule 20 mg Oral

Indications

chronic kidney disease